Rigel Pharmaceuticals, Inc. (RIGL) 10-Year Financial Performance & Capital Metrics

RIGL • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutRigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.Show more

Revenue $179M +53.4%
EBITDA $26M +237.2%
Net Income $17M +169.7%
EPS (Diluted) 0.99 +168.7%
Gross Margin 89.6% -4.6%
EBITDA Margin 14.74% +189.5%
Operating Margin 13.49% +177.0%
Net Margin 9.75% +145.4%
ROE 531.78%
ROIC 641.58% +154.8%
Debt/Equity 18.24
Interest Coverage 3.06 +202.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 17.3% free cash flow margin
✓Momentum leader: RS Rating 88 (top 12%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 24.8%
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗High debt to equity ratio of 18.2x
✗Expensive at 203.2x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y36.05%

5Y24.77%

3Y6.3%

TTM79.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM2819.35%

EPS CAGR

10Y-

5Y-

3Y-

TTM2805.98%

ROCE

10Y Avg-49.01%

5Y Avg-23.32%

3Y Avg-21.9%

Latest29.39%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	28.89M	20.38M	4.48M	44.51M	59.29M	108.62M	149.24M	120.24M	116.88M	179.28M
Revenue Growth %	2.5%	-0.29%	-0.78%	8.93%	0.33%	0.83%	0.37%	-0.19%	-0.03%	0.53%
Cost of Goods Sold+	62.83M	63.45M	46.27M	287K	906K	895K	1.08M	1.75M	7.11M	18.65M
COGS % of Revenue	2.17%	3.11%	10.32%	0.01%	0.02%	0.01%	0.01%	0.01%	0.06%	0.1%
Gross Profit+	-33.93M	-43.06M	-41.78M	44.22M	58.38M	107.73M	148.15M	118.49M	109.77M	160.63M
Gross Margin %	-1.17%	-2.11%	-9.32%	0.99%	0.98%	0.99%	0.99%	0.99%	0.94%	0.9%
Gross Profit Growth %	0.43%	-0.27%	0.03%	2.06%	0.32%	0.85%	0.38%	-0.2%	-0.07%	0.46%
Operating Expenses+	80.64M	90.12M	84.1M	116.91M	127.47M	136.7M	160.65M	174.04M	130.26M	136.44M
OpEx % of Revenue	2.79%	4.42%	18.76%	2.63%	2.15%	1.26%	1.08%	1.45%	1.11%	0.76%
Selling, General & Admin	17.81M	20.91M	37.83M	70M	74.59M	76.6M	91.89M	112.45M	105.74M	113.06M
SG&A % of Revenue	0.62%	1.03%	8.44%	1.57%	1.26%	0.71%	0.62%	0.94%	0.9%	0.63%
Research & Development	62.83M	63.45M	46.27M	46.9M	52.88M	60.1M	65.24M	60.27M	24.52M	23.38M
R&D % of Revenue	2.17%	3.11%	10.32%	1.05%	0.89%	0.55%	0.44%	0.5%	0.21%	0.13%
Other Operating Expenses	0	5.77M	0	0	0	0	3.52M	1.32M	0	0
Operating Income+	-51.74M	-69.74M	-79.62M	-72.68M	-69.09M	-28.97M	-12.5M	-55.55M	-20.49M	24.19M
Operating Margin %	-1.79%	-3.42%	-17.76%	-1.63%	-1.17%	-0.27%	-0.08%	-0.46%	-0.18%	0.13%
Operating Income Growth %	0.43%	-0.35%	-0.14%	0.09%	0.05%	0.58%	0.57%	-3.45%	0.63%	2.18%
EBITDA+	-50.3M	-68.8M	-79.15M	-72.09M	-68.41M	-28.27M	-11.33M	-54.55M	-19.25M	26.42M
EBITDA Margin %	-1.74%	-3.38%	-17.65%	-1.62%	-1.15%	-0.26%	-0.08%	-0.45%	-0.16%	0.15%
EBITDA Growth %	0.43%	-0.37%	-0.15%	0.09%	0.05%	0.59%	0.6%	-3.81%	0.65%	2.37%
D&A (Non-Cash Add-back)	1.44M	941K	465K	594K	683K	706K	1.16M	998K	1.24M	2.23M
EBIT	-51.74M	-63.97M	-77.99M	-70.48M	-66.56M	-28.39M	-12.45M	-54.87M	-18.22M	26.28M
Net Interest Income+	222K	437K	892K	2.2M	2.2M	-771K	-4.81M	-3.02M	-4.6M	-5.83M
Interest Income	222K	437K	892K	2.2M	2.53M	582K	47K	684K	2.27M	2.09M
Interest Expense	0	0	0	0	335K	1.35M	4.86M	3.71M	6.87M	7.92M
Other Income/Expense	279K	525K	1.62M	2.2M	2.2M	-771K	-4.81M	-3.02M	-4.6M	-5.83M
Pretax Income+	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.31M	-58.57M	-25.09M	18.37M
Pretax Margin %	-1.78%	-3.4%	-17.39%	-1.58%	-1.13%	-0.27%	-0.12%	-0.49%	-0.21%	0.1%
Income Tax+	0	0	0	0	0	0	605K	0	0	881K
Effective Tax Rate %	1%	1%	1%	1%	0.99%	1%	1.03%	1%	1%	0.95%
Net Income+	-51.46M	-69.22M	-77.99M	-70.48M	-66.55M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Net Margin %	-1.78%	-3.4%	-17.39%	-1.58%	-1.12%	-0.27%	-0.12%	-0.49%	-0.21%	0.1%
Net Income Growth %	0.43%	-0.34%	-0.13%	0.1%	0.06%	0.55%	0.4%	-2.27%	0.57%	1.7%
Net Income (Continuing)	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.82	-7.33	-6.17	-4.40	-4.00	-1.80	-1.10	-3.40	-1.44	0.99
EPS Growth %	0.44%	-0.26%	0.16%	0.29%	0.09%	0.55%	0.39%	-2.09%	0.58%	1.69%
EPS (Basic)	-5.82	-7.33	-6.17	-4.40	-4.00	-1.80	-1.10	-3.40	-1.44	0.99
Diluted Shares Outstanding	8.84M	9.44M	12.63M	16.05M	16.74M	16.88M	17.05M	17.24M	17.4M	17.69M
Basic Shares Outstanding	8.84M	9.44M	12.63M	16.05M	16.72M	16.88M	17.05M	17.24M	17.4M	17.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	129.02M	76.21M	117.43M	136.99M	119M	88.98M	154.47M	115.9M	99.27M	135.1M
Cash & Short-Term Investments	126.28M	74.77M	115.75M	128.54M	98.08M	57.33M	124.97M	58.21M	56.93M	77.32M
Cash Only	43.46M	17.63M	38.29M	76.32M	22.52M	30.37M	18.89M	24.46M	32.79M	56.75M
Short-Term Investments	82.82M	57.13M	77.46M	52.22M	75.56M	26.95M	106.08M	33.75M	24.15M	20.57M
Accounts Receivable	203K	0	0	4.08M	10.11M	15.97M	15.47M	40.32M	30.55M	41.62M
Days Sales Outstanding	2.56	-	-	33.43	62.25	53.67	37.84	122.39	95.4	84.73
Inventory	0	0	0	894K	1.35M	1.64M	6.62M	9.12M	5.52M	6M
Days Inventory Outstanding	-	-	-	1.14K	545.49	668.01	2.23K	1.9K	283.48	117.48
Other Current Assets	2.54M	1.45M	1.68M	3.48M	0	0	0	8.26M	6.26M	10.16M
Total Non-Current Assets+	2.72M	1.92M	1.68M	2.12M	28.56M	21.39M	12.86M	18.38M	17.96M	28.87M
Property, Plant & Equipment	1.61M	1.16M	875K	1.39M	27.87M	20.57M	11.89M	2.79M	1.03M	338K
Fixed Asset Turnover	17.91x	17.63x	5.12x	32.09x	2.13x	5.28x	12.55x	43.14x	113.92x	530.41x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	14.95M	13.88M	27.1M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.11M	764K	803K	735K	696K	824K	974K	640K	3.06M	1.44M
Total Assets+	131.75M	78.13M	119.11M	139.11M	147.57M	110.38M	167.33M	134.28M	117.22M	163.98M
Asset Turnover	0.22x	0.26x	0.04x	0.32x	0.40x	0.98x	0.89x	0.90x	1.00x	1.09x
Asset Growth %	-0.15%	-0.41%	0.52%	0.17%	0.06%	-0.25%	0.52%	-0.2%	-0.13%	0.4%
Total Current Liabilities+	33.8M	22.59M	18.34M	27.73M	58.21M	40.84M	63.55M	65.21M	53.27M	63.3M
Accounts Payable	2.76M	5.56M	2.64M	6.39M	4.15M	3.71M	3.79M	22.51M	7.14M	3.34M
Days Payables Outstanding	16.05	32	20.79	8.13K	1.67K	1.51K	1.28K	4.7K	366.64	65.36
Short-Term Debt	0	0	0	0	0	0	0	0	7.23M	7.27M
Deferred Revenue (Current)	1000K	-1000K	-284K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	11.52M	6.03M	284K	10.36M	8.82M	9.59M	24.2M	13.86M	12.32M	10.14M
Current Ratio	3.82x	3.37x	6.40x	4.94x	2.04x	2.18x	2.43x	1.78x	1.86x	2.13x
Quick Ratio	3.82x	3.37x	6.40x	4.91x	2.02x	2.14x	2.33x	1.64x	1.76x	2.04x
Cash Conversion Cycle	-	-	-	-6.96K	-1.06K	-790.11	988.59	-2.67K	12.24	136.85
Total Non-Current Liabilities+	6.57M	519K	128K	1.5M	35.54M	35.51M	73.4M	82.68M	92.6M	97.39M
Long-Term Debt	0	0	0	0	9.81M	19.82M	19.91M	39.45M	52.37M	52.41M
Capital Lease Obligations	0	0	0	0	19.23M	10.65M	759K	972K	285K	0
Deferred Tax Liabilities	-6.54M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.57M	519K	128K	90K	5.1M	5.04M	52.73M	42.26M	39.94M	44.98M
Total Liabilities	40.37M	23.11M	18.46M	29.23M	93.75M	76.35M	136.95M	147.9M	145.87M	160.69M
Total Debt+	6.46M	3.46M	284K	0	36.31M	39.09M	30.57M	41.55M	60.58M	59.97M
Net Debt	-36.99M	-14.17M	-38.01M	-76.32M	13.79M	8.71M	11.68M	17.09M	27.79M	3.22M
Debt / Equity	0.07x	0.06x	0.00x	-	0.67x	1.15x	1.01x	-	-	18.24x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	2.27x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.12x
Interest Coverage	-	-	-	-	-206.24x	-21.41x	-2.57x	-14.99x	-2.98x	3.06x
Total Equity+	91.38M	55.03M	100.65M	109.88M	53.81M	34.03M	30.37M	-13.62M	-28.64M	3.29M
Equity Growth %	-0.29%	-0.4%	0.83%	0.09%	-0.51%	-0.37%	-0.11%	-1.45%	-1.1%	1.11%
Book Value per Share	10.33	5.83	7.97	6.84	3.21	2.02	1.78	-0.79	-1.65	0.19
Total Shareholders' Equity	91.38M	55.03M	100.65M	109.88M	53.81M	34.03M	30.37M	-13.62M	-28.64M	3.29M
Common Stock	91K	100K	147K	167K	168K	169K	172K	174K	17K	18K
Retained Earnings	-991.65M	-1.06B	-1.14B	-1.21B	-1.28B	-1.31B	-1.32B	-1.38B	-1.41B	-1.39B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-44K	-18K	-82K	-24K	23K	-4K	-102K	-153K	8K	10K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-23.41M	-75.89M	-77.56M	-58.83M	-41.51M	-52.19M	5.88M	-73.76M	-5.74M	31.47M
Operating CF Margin %	-0.81%	-3.72%	-17.3%	-1.32%	-0.7%	-0.48%	0.04%	-0.61%	-0.05%	0.18%
Operating CF Growth %	0.66%	-2.24%	-0.02%	0.24%	0.29%	-0.26%	1.11%	-13.55%	0.92%	6.48%
Net Income	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Depreciation & Amortization	1.44M	941K	465K	594K	683K	706K	1.16M	998K	1.24M	2.23M
Stock-Based Compensation	7.4M	7.33M	5.99M	7.7M	9.12M	7.3M	9.49M	12.38M	8.81M	12.39M
Deferred Taxes	0	27K	-1.08M	0	0	0	0	0	0	0
Other Non-Cash Items	-57K	818K	495K	-766K	-1.07M	-122K	3.43M	481K	-213K	-788K
Working Capital Changes	19.27M	-15.79M	-5.43M	4.12M	16.66M	-30.32M	9.72M	-29.05M	9.52M	153K
Change in Receivables	5.55M	203K	0	-4.08M	-6.03M	-5.86M	501K	-24.85M	9.77M	-11.06M
Change in Inventory	801K	2.09M	0	-839K	-366K	-126K	-4.88M	-2.38M	1.17M	764K
Change in Payables	1.15M	2.8M	-2.95M	3.75M	-2.24M	-331K	41K	3.79M	-366K	-3.8M
Cash from Investing+	44.61M	24.88M	-19.47M	24.96M	-23.66M	47.47M	-80.04M	72.78M	-4.3M	4.13M
Capital Expenditures	-546K	-804K	-164K	-1.11M	-1.46M	-1.26M	-627K	-450K	-15M	-396K
CapEx % of Revenue	0.02%	0.04%	0.04%	0.02%	0.02%	0.01%	0%	0%	0.13%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	60K	88K	732K	-1.11M	0	0	0	893K	259K	98K
Cash from Financing+	7.05M	25.18M	117.69M	71.89M	11.37M	12.57M	62.67M	6.55M	18.37M	-11.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.76M	1.6M	3.51M	4.73M	1.58M	2.6M	62.67M	-12.99M	-1.58M	-1.64M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.96M	-76.69M	-77.72M	-59.93M	-42.97M	-53.45M	5.25M	-74.21M	-20.74M	31.07M
FCF Margin %	-0.83%	-3.76%	-17.33%	-1.35%	-0.72%	-0.49%	0.04%	-0.62%	-0.18%	0.17%
FCF Growth %	0.66%	-2.2%	-0.01%	0.23%	0.28%	-0.24%	1.1%	-15.13%	0.72%	2.5%
FCF per Share	-2.71	-8.13	-6.15	-3.73	-2.57	-3.17	0.31	-4.30	-1.19	1.76
FCF Conversion (FCF/Net Income)	0.45x	1.10x	0.99x	0.83x	0.62x	1.75x	-0.33x	1.26x	0.23x	1.80x
Interest Paid	0	0	0	0	137K	1.18M	1.5M	2.5M	5.85M	7.04M
Taxes Paid	0	0	0	0	0	0	0	0	0	331K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.86%	-94.55%	-100.2%	-66.96%	-81.31%	-67.72%	-55.63%	-699.05%	-	531.78%
Return on Invested Capital (ROIC)	-43.92%	-109.83%	-115.39%	-113.34%	-102.45%	-39.38%	-22.11%	-183.02%	-1170.02%	641.58%
Gross Margin	-117.43%	-211.27%	-931.87%	99.36%	98.47%	99.18%	99.27%	98.55%	93.92%	89.6%
Net Margin	-178.11%	-339.58%	-1739.34%	-158.35%	-112.24%	-27.38%	-12%	-48.71%	-21.47%	9.75%
Debt / Equity	0.07x	0.06x	0.00x	-	0.67x	1.15x	1.01x	-	-	18.24x
Interest Coverage	-	-	-	-	-206.24x	-21.41x	-2.57x	-14.99x	-2.98x	3.06x
FCF Conversion	0.45x	1.10x	0.99x	0.83x	0.62x	1.75x	-0.33x	1.26x	0.23x	1.80x
Revenue Growth	250.24%	-29.46%	-78%	892.62%	33.2%	83.21%	37.39%	-19.43%	-2.79%	53.38%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Gross product sales	-	-	-	81.19M	108.52M	147.06M	209.92M
Gross product sales Growth	-	-	-	-	33.67%	35.51%	42.75%
Product sales, net	-	-	-	63.01M	76.72M	104.29M	144.9M
Product sales, net Growth	-	-	-	-	21.76%	35.94%	38.94%
Contract revenues from collaborations	-	-	-	75.73M	39.02M	-	34.38M
Contract revenues from collaborations Growth	-	-	-	-	-48.47%	-	-
License	30.56M	8.7M	40.36M	-	-	-	14M
License Growth	-	-71.55%	364.10%	-	-	-	-
Discounts and allowances	-	-	-	-18.18M	-31.8M	-42.76M	-65.02M
Discounts and allowances Growth	-	-	-	-	-74.98%	-34.46%	-52.05%
Revenues from collaborations	-	-	-	-	-	11.49M	-
Revenues from collaborations Growth	-	-	-	-	-	-	-
Government contracts	-	-	-	-	-	1.1M	-
Government contracts Growth	-	-	-	-	-	-	-
Milestone	-	-	-	-	-	75K	-
Milestone Growth	-	-	-	-	-	-	-
Development milestones	-	-	-	1.88M	25M	-	-
Development milestones Growth	-	-	-	-	1233.33%	-	-
License revenues	-	-	-	70.55M	7.93M	-	-
License revenues Growth	-	-	-	-	-88.76%	-	-
Research and development services and others	-	-	-	3.3M	6.09M	-	-
Research and development services and others Growth	-	-	-	-	84.72%	-	-
Government contract	-	-	-	10.5M	4.5M	-	-
Government contract Growth	-	-	-	-	-57.14%	-	-
Gross Product	16.95M	53.08M	76.47M	-	-	-	-
Gross Product Growth	-	213.11%	44.06%	-	-	-	-
Product	13.95M	43.77M	61.7M	-	-	-	-
Product Growth	-	213.85%	40.95%	-	-	-	-
Contract Revenues From Collaborations	30.56M	15.52M	46.92M	-	-	-	-
Contract Revenues From Collaborations Growth	-	-49.23%	202.43%	-	-	-	-
Research And Development Services And Others	-	1.32M	4.47M	-	-	-	-
Research And Development Services And Others Growth	-	-	238.41%	-	-	-	-
Development Milestones	-	5.5M	2.1M	-	-	-	-
Development Milestones Growth	-	-	-61.82%	-	-	-	-
Discounts And Allowances	-3.01M	-9.31M	-14.77M	-	-	-	-
Discounts And Allowances Growth	-	-209.71%	-58.69%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Rigel Pharmaceuticals, Inc. (RIGL) has a price-to-earnings (P/E) ratio of 38.2x. This suggests investors expect higher future growth.

Growth & Financials

Rigel Pharmaceuticals, Inc. (RIGL) reported $282.1M in revenue for fiscal year 2024. This represents a 5838% increase from $4.8M in 2011.

Rigel Pharmaceuticals, Inc. (RIGL) grew revenue by 53.4% over the past year. This is strong growth.

Yes, Rigel Pharmaceuticals, Inc. (RIGL) is profitable, generating $113.3M in net income for fiscal year 2024 (9.8% net margin).

Dividend & Returns

Rigel Pharmaceuticals, Inc. (RIGL) has a return on equity (ROE) of 531.8%. This is excellent, indicating efficient use of shareholder capital.

Rigel Pharmaceuticals, Inc. (RIGL) generated $68.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Rigel Pharmaceuticals, Inc. (RIGL) 10-Year Financial Performance & Capital Metrics

RIGL • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

Revenue $179M +53.4%
EBITDA $26M +237.2%
Net Income $17M +169.7%
EPS (Diluted) 0.99 +168.7%
Gross Margin 89.6% -4.6%
EBITDA Margin 14.74% +189.5%
Operating Margin 13.49% +177.0%
Net Margin 9.75% +145.4%
ROE 531.78%
ROIC 641.58% +154.8%
Debt/Equity 18.24
Interest Coverage 3.06 +202.5%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 7/9
✓FCF machine: 17.3% free cash flow margin
✓Momentum leader: RS Rating 88 (top 12%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 24.8%
✓Efficient asset utilization: 1.1x turnover

✗Weaknesses

✗High debt to equity ratio of 18.2x
✗Expensive at 203.2x book value

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y36.05%

5Y24.77%

3Y6.3%

TTM79.13%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM2819.35%

EPS CAGR

10Y-

5Y-

3Y-

TTM2805.98%

ROCE

10Y Avg-49.01%

5Y Avg-23.32%

3Y Avg-21.9%

Latest29.39%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	28.89M	20.38M	4.48M	44.51M	59.29M	108.62M	149.24M	120.24M	116.88M	179.28M
Revenue Growth %	2.5%	-0.29%	-0.78%	8.93%	0.33%	0.83%	0.37%	-0.19%	-0.03%	0.53%
Cost of Goods Sold+	62.83M	63.45M	46.27M	287K	906K	895K	1.08M	1.75M	7.11M	18.65M
COGS % of Revenue	2.17%	3.11%	10.32%	0.01%	0.02%	0.01%	0.01%	0.01%	0.06%	0.1%
Gross Profit+	-33.93M	-43.06M	-41.78M	44.22M	58.38M	107.73M	148.15M	118.49M	109.77M	160.63M
Gross Margin %	-1.17%	-2.11%	-9.32%	0.99%	0.98%	0.99%	0.99%	0.99%	0.94%	0.9%
Gross Profit Growth %	0.43%	-0.27%	0.03%	2.06%	0.32%	0.85%	0.38%	-0.2%	-0.07%	0.46%
Operating Expenses+	80.64M	90.12M	84.1M	116.91M	127.47M	136.7M	160.65M	174.04M	130.26M	136.44M
OpEx % of Revenue	2.79%	4.42%	18.76%	2.63%	2.15%	1.26%	1.08%	1.45%	1.11%	0.76%
Selling, General & Admin	17.81M	20.91M	37.83M	70M	74.59M	76.6M	91.89M	112.45M	105.74M	113.06M
SG&A % of Revenue	0.62%	1.03%	8.44%	1.57%	1.26%	0.71%	0.62%	0.94%	0.9%	0.63%
Research & Development	62.83M	63.45M	46.27M	46.9M	52.88M	60.1M	65.24M	60.27M	24.52M	23.38M
R&D % of Revenue	2.17%	3.11%	10.32%	1.05%	0.89%	0.55%	0.44%	0.5%	0.21%	0.13%
Other Operating Expenses	0	5.77M	0	0	0	0	3.52M	1.32M	0	0
Operating Income+	-51.74M	-69.74M	-79.62M	-72.68M	-69.09M	-28.97M	-12.5M	-55.55M	-20.49M	24.19M
Operating Margin %	-1.79%	-3.42%	-17.76%	-1.63%	-1.17%	-0.27%	-0.08%	-0.46%	-0.18%	0.13%
Operating Income Growth %	0.43%	-0.35%	-0.14%	0.09%	0.05%	0.58%	0.57%	-3.45%	0.63%	2.18%
EBITDA+	-50.3M	-68.8M	-79.15M	-72.09M	-68.41M	-28.27M	-11.33M	-54.55M	-19.25M	26.42M
EBITDA Margin %	-1.74%	-3.38%	-17.65%	-1.62%	-1.15%	-0.26%	-0.08%	-0.45%	-0.16%	0.15%
EBITDA Growth %	0.43%	-0.37%	-0.15%	0.09%	0.05%	0.59%	0.6%	-3.81%	0.65%	2.37%
D&A (Non-Cash Add-back)	1.44M	941K	465K	594K	683K	706K	1.16M	998K	1.24M	2.23M
EBIT	-51.74M	-63.97M	-77.99M	-70.48M	-66.56M	-28.39M	-12.45M	-54.87M	-18.22M	26.28M
Net Interest Income+	222K	437K	892K	2.2M	2.2M	-771K	-4.81M	-3.02M	-4.6M	-5.83M
Interest Income	222K	437K	892K	2.2M	2.53M	582K	47K	684K	2.27M	2.09M
Interest Expense	0	0	0	0	335K	1.35M	4.86M	3.71M	6.87M	7.92M
Other Income/Expense	279K	525K	1.62M	2.2M	2.2M	-771K	-4.81M	-3.02M	-4.6M	-5.83M
Pretax Income+	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.31M	-58.57M	-25.09M	18.37M
Pretax Margin %	-1.78%	-3.4%	-17.39%	-1.58%	-1.13%	-0.27%	-0.12%	-0.49%	-0.21%	0.1%
Income Tax+	0	0	0	0	0	0	605K	0	0	881K
Effective Tax Rate %	1%	1%	1%	1%	0.99%	1%	1.03%	1%	1%	0.95%
Net Income+	-51.46M	-69.22M	-77.99M	-70.48M	-66.55M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Net Margin %	-1.78%	-3.4%	-17.39%	-1.58%	-1.12%	-0.27%	-0.12%	-0.49%	-0.21%	0.1%
Net Income Growth %	0.43%	-0.34%	-0.13%	0.1%	0.06%	0.55%	0.4%	-2.27%	0.57%	1.7%
Net Income (Continuing)	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-5.82	-7.33	-6.17	-4.40	-4.00	-1.80	-1.10	-3.40	-1.44	0.99
EPS Growth %	0.44%	-0.26%	0.16%	0.29%	0.09%	0.55%	0.39%	-2.09%	0.58%	1.69%
EPS (Basic)	-5.82	-7.33	-6.17	-4.40	-4.00	-1.80	-1.10	-3.40	-1.44	0.99
Diluted Shares Outstanding	8.84M	9.44M	12.63M	16.05M	16.74M	16.88M	17.05M	17.24M	17.4M	17.69M
Basic Shares Outstanding	8.84M	9.44M	12.63M	16.05M	16.72M	16.88M	17.05M	17.24M	17.4M	17.58M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	129.02M	76.21M	117.43M	136.99M	119M	88.98M	154.47M	115.9M	99.27M	135.1M
Cash & Short-Term Investments	126.28M	74.77M	115.75M	128.54M	98.08M	57.33M	124.97M	58.21M	56.93M	77.32M
Cash Only	43.46M	17.63M	38.29M	76.32M	22.52M	30.37M	18.89M	24.46M	32.79M	56.75M
Short-Term Investments	82.82M	57.13M	77.46M	52.22M	75.56M	26.95M	106.08M	33.75M	24.15M	20.57M
Accounts Receivable	203K	0	0	4.08M	10.11M	15.97M	15.47M	40.32M	30.55M	41.62M
Days Sales Outstanding	2.56	-	-	33.43	62.25	53.67	37.84	122.39	95.4	84.73
Inventory	0	0	0	894K	1.35M	1.64M	6.62M	9.12M	5.52M	6M
Days Inventory Outstanding	-	-	-	1.14K	545.49	668.01	2.23K	1.9K	283.48	117.48
Other Current Assets	2.54M	1.45M	1.68M	3.48M	0	0	0	8.26M	6.26M	10.16M
Total Non-Current Assets+	2.72M	1.92M	1.68M	2.12M	28.56M	21.39M	12.86M	18.38M	17.96M	28.87M
Property, Plant & Equipment	1.61M	1.16M	875K	1.39M	27.87M	20.57M	11.89M	2.79M	1.03M	338K
Fixed Asset Turnover	17.91x	17.63x	5.12x	32.09x	2.13x	5.28x	12.55x	43.14x	113.92x	530.41x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	14.95M	13.88M	27.1M
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	1.11M	764K	803K	735K	696K	824K	974K	640K	3.06M	1.44M
Total Assets+	131.75M	78.13M	119.11M	139.11M	147.57M	110.38M	167.33M	134.28M	117.22M	163.98M
Asset Turnover	0.22x	0.26x	0.04x	0.32x	0.40x	0.98x	0.89x	0.90x	1.00x	1.09x
Asset Growth %	-0.15%	-0.41%	0.52%	0.17%	0.06%	-0.25%	0.52%	-0.2%	-0.13%	0.4%
Total Current Liabilities+	33.8M	22.59M	18.34M	27.73M	58.21M	40.84M	63.55M	65.21M	53.27M	63.3M
Accounts Payable	2.76M	5.56M	2.64M	6.39M	4.15M	3.71M	3.79M	22.51M	7.14M	3.34M
Days Payables Outstanding	16.05	32	20.79	8.13K	1.67K	1.51K	1.28K	4.7K	366.64	65.36
Short-Term Debt	0	0	0	0	0	0	0	0	7.23M	7.27M
Deferred Revenue (Current)	1000K	-1000K	-284K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	11.52M	6.03M	284K	10.36M	8.82M	9.59M	24.2M	13.86M	12.32M	10.14M
Current Ratio	3.82x	3.37x	6.40x	4.94x	2.04x	2.18x	2.43x	1.78x	1.86x	2.13x
Quick Ratio	3.82x	3.37x	6.40x	4.91x	2.02x	2.14x	2.33x	1.64x	1.76x	2.04x
Cash Conversion Cycle	-	-	-	-6.96K	-1.06K	-790.11	988.59	-2.67K	12.24	136.85
Total Non-Current Liabilities+	6.57M	519K	128K	1.5M	35.54M	35.51M	73.4M	82.68M	92.6M	97.39M
Long-Term Debt	0	0	0	0	9.81M	19.82M	19.91M	39.45M	52.37M	52.41M
Capital Lease Obligations	0	0	0	0	19.23M	10.65M	759K	972K	285K	0
Deferred Tax Liabilities	-6.54M	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	6.57M	519K	128K	90K	5.1M	5.04M	52.73M	42.26M	39.94M	44.98M
Total Liabilities	40.37M	23.11M	18.46M	29.23M	93.75M	76.35M	136.95M	147.9M	145.87M	160.69M
Total Debt+	6.46M	3.46M	284K	0	36.31M	39.09M	30.57M	41.55M	60.58M	59.97M
Net Debt	-36.99M	-14.17M	-38.01M	-76.32M	13.79M	8.71M	11.68M	17.09M	27.79M	3.22M
Debt / Equity	0.07x	0.06x	0.00x	-	0.67x	1.15x	1.01x	-	-	18.24x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	2.27x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	0.12x
Interest Coverage	-	-	-	-	-206.24x	-21.41x	-2.57x	-14.99x	-2.98x	3.06x
Total Equity+	91.38M	55.03M	100.65M	109.88M	53.81M	34.03M	30.37M	-13.62M	-28.64M	3.29M
Equity Growth %	-0.29%	-0.4%	0.83%	0.09%	-0.51%	-0.37%	-0.11%	-1.45%	-1.1%	1.11%
Book Value per Share	10.33	5.83	7.97	6.84	3.21	2.02	1.78	-0.79	-1.65	0.19
Total Shareholders' Equity	91.38M	55.03M	100.65M	109.88M	53.81M	34.03M	30.37M	-13.62M	-28.64M	3.29M
Common Stock	91K	100K	147K	167K	168K	169K	172K	174K	17K	18K
Retained Earnings	-991.65M	-1.06B	-1.14B	-1.21B	-1.28B	-1.31B	-1.32B	-1.38B	-1.41B	-1.39B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-44K	-18K	-82K	-24K	23K	-4K	-102K	-153K	8K	10K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-23.41M	-75.89M	-77.56M	-58.83M	-41.51M	-52.19M	5.88M	-73.76M	-5.74M	31.47M
Operating CF Margin %	-0.81%	-3.72%	-17.3%	-1.32%	-0.7%	-0.48%	0.04%	-0.61%	-0.05%	0.18%
Operating CF Growth %	0.66%	-2.24%	-0.02%	0.24%	0.29%	-0.26%	1.11%	-13.55%	0.92%	6.48%
Net Income	-51.46M	-69.22M	-77.99M	-70.48M	-66.89M	-29.74M	-17.91M	-58.57M	-25.09M	17.48M
Depreciation & Amortization	1.44M	941K	465K	594K	683K	706K	1.16M	998K	1.24M	2.23M
Stock-Based Compensation	7.4M	7.33M	5.99M	7.7M	9.12M	7.3M	9.49M	12.38M	8.81M	12.39M
Deferred Taxes	0	27K	-1.08M	0	0	0	0	0	0	0
Other Non-Cash Items	-57K	818K	495K	-766K	-1.07M	-122K	3.43M	481K	-213K	-788K
Working Capital Changes	19.27M	-15.79M	-5.43M	4.12M	16.66M	-30.32M	9.72M	-29.05M	9.52M	153K
Change in Receivables	5.55M	203K	0	-4.08M	-6.03M	-5.86M	501K	-24.85M	9.77M	-11.06M
Change in Inventory	801K	2.09M	0	-839K	-366K	-126K	-4.88M	-2.38M	1.17M	764K
Change in Payables	1.15M	2.8M	-2.95M	3.75M	-2.24M	-331K	41K	3.79M	-366K	-3.8M
Cash from Investing+	44.61M	24.88M	-19.47M	24.96M	-23.66M	47.47M	-80.04M	72.78M	-4.3M	4.13M
Capital Expenditures	-546K	-804K	-164K	-1.11M	-1.46M	-1.26M	-627K	-450K	-15M	-396K
CapEx % of Revenue	0.02%	0.04%	0.04%	0.02%	0.02%	0.01%	0%	0%	0.13%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	60K	88K	732K	-1.11M	0	0	0	893K	259K	98K
Cash from Financing+	7.05M	25.18M	117.69M	71.89M	11.37M	12.57M	62.67M	6.55M	18.37M	-11.64M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	1.76M	1.6M	3.51M	4.73M	1.58M	2.6M	62.67M	-12.99M	-1.58M	-1.64M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-23.96M	-76.69M	-77.72M	-59.93M	-42.97M	-53.45M	5.25M	-74.21M	-20.74M	31.07M
FCF Margin %	-0.83%	-3.76%	-17.33%	-1.35%	-0.72%	-0.49%	0.04%	-0.62%	-0.18%	0.17%
FCF Growth %	0.66%	-2.2%	-0.01%	0.23%	0.28%	-0.24%	1.1%	-15.13%	0.72%	2.5%
FCF per Share	-2.71	-8.13	-6.15	-3.73	-2.57	-3.17	0.31	-4.30	-1.19	1.76
FCF Conversion (FCF/Net Income)	0.45x	1.10x	0.99x	0.83x	0.62x	1.75x	-0.33x	1.26x	0.23x	1.80x
Interest Paid	0	0	0	0	137K	1.18M	1.5M	2.5M	5.85M	7.04M
Taxes Paid	0	0	0	0	0	0	0	0	0	331K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-46.86%	-94.55%	-100.2%	-66.96%	-81.31%	-67.72%	-55.63%	-699.05%	-	531.78%
Return on Invested Capital (ROIC)	-43.92%	-109.83%	-115.39%	-113.34%	-102.45%	-39.38%	-22.11%	-183.02%	-1170.02%	641.58%
Gross Margin	-117.43%	-211.27%	-931.87%	99.36%	98.47%	99.18%	99.27%	98.55%	93.92%	89.6%
Net Margin	-178.11%	-339.58%	-1739.34%	-158.35%	-112.24%	-27.38%	-12%	-48.71%	-21.47%	9.75%
Debt / Equity	0.07x	0.06x	0.00x	-	0.67x	1.15x	1.01x	-	-	18.24x
Interest Coverage	-	-	-	-	-206.24x	-21.41x	-2.57x	-14.99x	-2.98x	3.06x
FCF Conversion	0.45x	1.10x	0.99x	0.83x	0.62x	1.75x	-0.33x	1.26x	0.23x	1.80x
Revenue Growth	250.24%	-29.46%	-78%	892.62%	33.2%	83.21%	37.39%	-19.43%	-2.79%	53.38%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Gross product sales	-	-	-	81.19M	108.52M	147.06M	209.92M
Gross product sales Growth	-	-	-	-	33.67%	35.51%	42.75%
Product sales, net	-	-	-	63.01M	76.72M	104.29M	144.9M
Product sales, net Growth	-	-	-	-	21.76%	35.94%	38.94%
Contract revenues from collaborations	-	-	-	75.73M	39.02M	-	34.38M
Contract revenues from collaborations Growth	-	-	-	-	-48.47%	-	-
License	30.56M	8.7M	40.36M	-	-	-	14M
License Growth	-	-71.55%	364.10%	-	-	-	-
Discounts and allowances	-	-	-	-18.18M	-31.8M	-42.76M	-65.02M
Discounts and allowances Growth	-	-	-	-	-74.98%	-34.46%	-52.05%
Revenues from collaborations	-	-	-	-	-	11.49M	-
Revenues from collaborations Growth	-	-	-	-	-	-	-
Government contracts	-	-	-	-	-	1.1M	-
Government contracts Growth	-	-	-	-	-	-	-
Milestone	-	-	-	-	-	75K	-
Milestone Growth	-	-	-	-	-	-	-
Development milestones	-	-	-	1.88M	25M	-	-
Development milestones Growth	-	-	-	-	1233.33%	-	-
License revenues	-	-	-	70.55M	7.93M	-	-
License revenues Growth	-	-	-	-	-88.76%	-	-
Research and development services and others	-	-	-	3.3M	6.09M	-	-
Research and development services and others Growth	-	-	-	-	84.72%	-	-
Government contract	-	-	-	10.5M	4.5M	-	-
Government contract Growth	-	-	-	-	-57.14%	-	-
Gross Product	16.95M	53.08M	76.47M	-	-	-	-
Gross Product Growth	-	213.11%	44.06%	-	-	-	-
Product	13.95M	43.77M	61.7M	-	-	-	-
Product Growth	-	213.85%	40.95%	-	-	-	-
Contract Revenues From Collaborations	30.56M	15.52M	46.92M	-	-	-	-
Contract Revenues From Collaborations Growth	-	-49.23%	202.43%	-	-	-	-
Research And Development Services And Others	-	1.32M	4.47M	-	-	-	-
Research And Development Services And Others Growth	-	-	238.41%	-	-	-	-
Development Milestones	-	5.5M	2.1M	-	-	-	-
Development Milestones Growth	-	-	-61.82%	-	-	-	-
Discounts And Allowances	-3.01M	-9.31M	-14.77M	-	-	-	-
Discounts And Allowances Growth	-	-209.71%	-58.69%	-	-	-	-

Frequently Asked Questions

Valuation & Price

Rigel Pharmaceuticals, Inc. (RIGL) has a price-to-earnings (P/E) ratio of 38.2x. This suggests investors expect higher future growth.

Growth & Financials

Rigel Pharmaceuticals, Inc. (RIGL) reported $282.1M in revenue for fiscal year 2024. This represents a 5838% increase from $4.8M in 2011.

Rigel Pharmaceuticals, Inc. (RIGL) grew revenue by 53.4% over the past year. This is strong growth.

Yes, Rigel Pharmaceuticals, Inc. (RIGL) is profitable, generating $113.3M in net income for fiscal year 2024 (9.8% net margin).

Dividend & Returns

Rigel Pharmaceuticals, Inc. (RIGL) has a return on equity (ROE) of 531.8%. This is excellent, indicating efficient use of shareholder capital.

Rigel Pharmaceuticals, Inc. (RIGL) generated $68.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.